- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
CIBC Private Wealth Group Boosts Neurocrine Biosciences Stock Holdings
Investment firm increases stake in biopharmaceutical company by over 17,000%
Mar. 23, 2026 at 7:33am
Got story updates? Submit your updates here. ›
CIBC Private Wealth Group LLC significantly increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter of 2025, boosting its position by 17,250% to 7,981 shares worth $1.12 million. The move comes as the biopharmaceutical company continues to see strong investor interest in its pipeline of neurological and endocrine disorder treatments.
Why it matters
Neurocrine Biosciences is a prominent player in the biotech industry, known for its focus on developing treatments for movement disorders, reproductive health issues, and central nervous system conditions. The substantial increase in CIBC Private Wealth Group's stake suggests growing confidence in the company's future prospects and product portfolio.
The details
According to the regulatory filing, CIBC Private Wealth Group added 7,935 shares of Neurocrine Biosciences during the third quarter, bringing its total holdings to 7,981 shares. This represents a massive 17,250% increase compared to the previous quarter. The investment firm's position in Neurocrine Biosciences was valued at $1.12 million at the end of the reporting period.
- CIBC Private Wealth Group LLC increased its Neurocrine Biosciences holdings during the third quarter of 2025.
The players
CIBC Private Wealth Group LLC
An investment management firm that is a subsidiary of Canadian Imperial Bank of Commerce (CIBC).
Neurocrine Biosciences, Inc.
A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders.
The takeaway
The significant increase in CIBC Private Wealth Group's stake in Neurocrine Biosciences suggests the investment firm sees strong potential in the biopharmaceutical company's pipeline and future growth prospects. This move underscores the broader investor interest in Neurocrine Biosciences as it continues to advance its treatments for various neurological and endocrine conditions.
